Key result
Beta-blockers are linked to ~90% lower AF risk in wtATTR-CM, whereas CKD predicts higher risk.
Why the study?
wtATTR-CM predisposes patients to a high incidence of AF, making the identification of clinical, pharmacologic, and echocardiographic predictors crucial for early intervention and risk stratification.
What are the clinical, pharmacologic, and echocardiographic predictors of incident atrial fibrillation in patients with wild-type transthyretin amyloid cardiomyopathy?
Population
59 wtATTR-CM patients in sinus rhythm at diagnosis
Comparison
Patients who developed incident AF vs those who did not
Design
Retrospective single-center study
Follow-up
Median 30 months (IQR 16–36)
Authors
Loading...
CKD may warrant closer AF monitoring in wtATTR-CM; observational data leaves open causality and beta-blocker effects pending trials.
Cohort (n=59)
No
What are the clinical, pharmacologic, and echocardiographic predictors of incident atrial fibrillation in patients with wild-type transthyretin amyloid cardiomyopathy?
Odds Ratio: 6.2 (95% CI 1.28–30.14)
p-value: p=0.04
In patients with wild-type transthyretin amyloid cardiomyopathy, incident atrial fibrillation is common and can be predicted by the presence of CKD, lack of beta-blocker use, and echocardiographic markers of diastolic dysfunction and impaired atrial strain.
Pinheiro et al. (2026) conducted a cohort in wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM) (n=59). Chronic kidney disease vs. Absence of chronic kidney disease was evaluated on incident atrial fibrillation (OR 6.20, 95% CI 1.28-30.14, p=0.04). In patients with wtATTR-CM, chronic kidney disease independently predicted incident atrial fibrillation (OR 6.20; 95% CI 1.28-30.14; p=0.04), while beta-blocker use was associated with lower risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: